NRIX supply chain intelligence for Nurix Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Nurix Therapeutics, Inc. (NRIX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PIPER-SANDLER-CO | PIPER-SANDLER-CO | 90% | the Company may offer and sell through Piper Sandler, as sales agent, $413.65 million of shares of the Company’s common stock |
| CCCC | C4 Therapeutics, Inc. | 72% | Reciprocal relationship from CCCC graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from CCCC graph: ies and no experience in marketing products. We intend to develop an in-hous… |
| CRIS | Curis, Inc. | 72% | Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, bot… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD g… |
| GILD | Gilead Sciences, Inc. | 72% | g Administration (FDA), the European Medicines Agency (EMA) or other regulatory authorities to perform trials in addition to those we currently expect, or if there are any delays in establishing appr… |
| GLUE | Monte Rosa Therapeutics, Inc. | 72% | Reciprocal relationship from GLUE graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alter… |
| KYMR | Kymera Therapeutics, Inc. | 72% | Reciprocal relationship from KYMR graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: , have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-… |
| SNYNF | Sanofi | 72% | , have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-funded warrants may not exercise the warrant if the holder, together with its affil… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| F-HOFFMANN-LA-ROCHE-LTD | F-HOFFMANN-LA-ROCHE-LTD | 92% | Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights |
| GENENTECH-INC | GENENTECH-INC | 92% | Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights |
| GILEAD | GILEAD | 92% | Under the Gilead Agreement, Gilead has the option to license drug candidates directed to up to five targets resulting from the collaboration and is responsible for the clinical development and commer… |
| SANOFI | SANOFI | 90% | In December 2019, we entered into a strategic collaboration with Genzyme Corporation, a subsidiary of Sanofi, which became effective in January 2020 |
| PFE | Pfizer Inc. | 85% | In our partnership with Pfizer, which was announced in September 2023 under an agreement with Seagen, Inc., we have achieved two preclinical milestones to date, qualifying for $10.0 million in milest… |
| PFE | Pfizer Inc. | 85% | Reciprocal relationship from PFE graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from PFE graph: Reciprocal relationship from NRIX graph: In our partnership with Pfizer, which… |
| GILD | Gilead Sciences, Inc. | 72% | g Administration (FDA), the European Medicines Agency (EMA) or other regulatory authorities to perform trials in addition to those we currently expect, or if there are any delays in establishing appr… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD g… |
| KYMR | Kymera Therapeutics, Inc. | 72% | Reciprocal relationship from KYMR graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term suppl… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | , have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-funded warrants may not exercise the warrant if the holder, together with its affil… |
| DELAWARE-GENERAL-CORPORATION | DELAWARE-GENERAL-CORPORATION | 62% | in connection with acquisitions include: • diversion of management time and focus from operating our business to addressing acquisition integration challenges; • coordination of research and developm… |
| SI | Shoulder Innovations, Inc. | 62% | Reciprocal relationship from SI graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from SI graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from SI graph: … |
| SILVERGATE-CAPITAL-CORP | SILVERGATE-CAPITAL-CORP | 62% | in connection with acquisitions include: • diversion of management time and focus from operating our business to addressing acquisition integration challenges; • coordination of research and developm… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NRIX-DEBT-11362 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-11-30. |
| NRIX-DEBT-11361 | Warrants outstanding: 94759000 | 90% | xbrl warrant detail from xbrl 2022-11-30. |
| NRIX-DEBT | Debt stack $58.7M | 90% | Market cache reports total debt of $58.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| NRIX-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 198 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| VEEV | Veeva Systems Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| FULC | Fulcrum Therapeutics, Inc. | 100.00 | 2 |